About The Doctor

Dr. Bruce Johnson

Thoracic Surgeon , Director, Lowe Center for Thoracic Oncology

The primary challenge of oncologists comes down to treating mesothelioma when the disease caused by asbestos has a resistance to most chemotherapeutic drugs. Dr. Bruce Johnson, M.D., says the key to successful treatment can be traced to remaining persistent and using genetic therapy that targets the problem. This will increase the accuracy and potency of the medicines used.

Get In Touch

A Fruitful Career

Dr. Bruce Johnson first started his research on gene therapy with the National Cancer Institute (NCI) in the 1980s. Later, he served as head of the NCI’s Lung Cancer Biology section. He held this position until he joined Harvard’s Dana-Farber Cancer Institute as Chief Clinical Research Officer.

Dr. Johnson has worked in the laboratory studying lung cancer with some of the brightest researchers in the field, including Pasi Jänne, PhD., who hopes that further research could eventually make gene therapy a leading treatment for lung cancer and other asbestos-related diseases.

Message of Hope

Dr. Bruce Johnson provides multidisciplinary care and considers demographics like age and gender when caring for each patient.

Patient Response

Dr. Bruce Johnson has also studied patient response to particular therapies. For example, one of his studies looked at how females who had adenocarcinoma but did not smoke had a favorable response to Erlotinib and Gefitinib.

Hopes for the Future

Dr. Johnson is a member of the External Scientific Committee and has built a foundation of research for his clinical treatment of patients. He hopes his genomics research will provide patients with better therapies.

Dr. Johnson strives to implement a multidisciplinary approach and consider demographics like age and gender when caring for each patient to provide his patients with the best care.

Article Sources